Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
31 authors.
Elham KazemianDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Qianxing MoDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.ORCID 0000-0002-0021-7694
Marco MatejcicGenomic Medicine Institute, Cleveland Clinic, Cleveland, OH, United States.ORCID 0009-0004-9468-0664
Ya-Yu TsaiGenomic Medicine Institute, Cleveland Clinic, Cleveland, OH, United States.ORCID 0000-0002-5085-6400
Daniel SobieskiGenomic Medicine Institute, Cleveland Clinic, Cleveland, OH, United States.
Xiaoyin LiDepartment of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.ORCID 0000-0001-8028-8910
Aasha I HooglandDepartment of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.ORCID 0000-0002-8691-8132
Sylvia L CrowderDepartment of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.ORCID 0000-0003-1430-9810
Brian D GonzalezDepartment of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.ORCID 0000-0001-5108-5735
Laura B OswaldDepartment of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.ORCID 0000-0001-6281-2512
Alix G SleightChan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA, United States.ORCID 0000-0001-5317-060X
Nathalie NguyenDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.ORCID 0009-0001-4282-103X
Nicole C LoroñaDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.ORCID 0000-0002-8302-3157
Victoria DamerellDepartment of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0003-0161-869X
Khaled R KomrokjiDepartment of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
Kathi MooneyCollege of Nursing and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.ORCID 0000-0003-3371-5646
Mary C PlaydonHuntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, UT, United States.ORCID 0000-0001-6082-0447
Cornelia M UlrichHuntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, UT, United States.ORCID 0000-0001-7641-059X
Christopher I LiPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0000-0003-1543-0743
David ShibataDepartment of Surgery, University of Tennessee Health Science Center, Memphis, TN, United States.ORCID 0000-0002-5670-423X
Adetunji T ToriolaDepartment of Surgery, Division of Public Health Sciences, and Siteman Cancer Center, Washington University, St Louis, MO, United States.ORCID 0000-0003-1079-2606
Jennifer OseHuntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, UT, United States.ORCID 0000-0002-2030-9676
Anita R PeoplesHuntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, UT, United States.ORCID 0000-0003-3645-3960
Sheetal HardikarHuntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, UT, United States.ORCID 0000-0003-0292-6168
Christoph KahlertDepartment of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Erin M SiegelDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States.ORCID 0000-0003-1779-2510
Julienne E BowerDepartment of Psychology, University of California Los Angeles, Los Angeles, CA, United States.ORCID 0000-0003-0813-4444
Stephanie L SchmitGenomic Medicine Institute, Cleveland Clinic, Cleveland, OH, United States.ORCID 0000-0001-5931-1194
Biljana GigicDepartment of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-8085-2072
Heather S L JimDepartment of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.ORCID 0000-0001-7353-3711
Jane C FigueiredoDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.ORCID 0000-0001-8040-3341
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Developing Data-Driven Cancer ResearchersT32CA009168 · NCI · UNIVERSITY OF WASHINGTON · PI STEPHEN M SCHWARTZ, MICHAEL Chiao-An WU · 1985 to 2026
$10.1M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Vascular Health and Risk Factors in Children with Down SyndromeKL2TR002539 · NCATS · UNIVERSITY OF UTAH · PI MURTAUGH, MAUREEN A, NYGAARD, INGRID E · 2018 to 2022
$4.3M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Novel Biomarkers for Cancer-Related Fatigue: Integrating Metabolomics, Genomics and BehaviorsR01NR018762 · NINR · CEDARS-SINAI MEDICAL CENTER · PI FIGUEIREDO, JANE C., JIM, HEATHER S.L. · 2020 to 2024
$3.4M
Adipose tissue-colorectal tumor cross-talk: new targets for breaking the obesity-cancer linkR01CA254108 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI HURSTING, STEPHEN D, ULRICH, CORNELIA M · 2021 to 2025
$3.2M
Training Program in Genomic MedicineT32HG008962 · NHGRI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Lynn Jorde, Aaron R Quinlan · 2016 to 2026
$3.0M
Geriatric assessment domains in relation to treatment outcomes among older adults with colorectal cancerR01AG083580 · NIA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Sheetal Hardikar · 2024 to 2026
$2.3M
Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP StudyR01CA211705 · NCI · UNIVERSITY OF UTAH · PI LASTAYO, PAUL C, ULRICH, CORNELIA M · 2017 to 2021
$2.2M
Global metabolomics profiling, dietary factors, and colorectal cancer risk in the NIH-Consortium of Metabolomics Studies (COMETS)R03CA270473 · NCI · UNIVERSITY OF UTAH · PI PLAYDON, MARY CHRISTINE · 2022 to 2023
$151k
Cancer Control and Population Health SciencesClaussen-Simon StiftungCore and Molecular Genomics Core FacilitiesGerman Cancer Research CenterGerman Consortium of Translational Cancer ResearchH. Lee Moffitt Cancer Center and Research InstituteH. Lee Moffitt Cancer Center & Research InstituteHuntsman Cancer Foundation, Immunology, Inflammation, and Infectious Disease InitiativeMatthias Lackas StiftungNCATS NIH HHS KL2 TR002539NCI NIH HHS 1A1 R01 CA189184NCI NIH HHS P30 CA076292NCI NIH HHS P30-CA076292NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS R01 CA211705NCI NIH HHS R01 CA254108NCI NIH HHS R03 CA270473NCI NIH HHS R2 U01 CA206110NCI NIH HHS T32 CA009168NCI NIH HHS T32CA009168NCI NIH HHS U01 CA206110NHGRI NIH HHS T32 HG008962NIA NIH HHS R01 AG083580NIH HHS KL2TR00-2539NIH HHS R01 CA189184NIH HHS R01 CA207371NIH HHS R01 CA211705NIH HHS R01 CA254108NIH HHS R03CA270473NIH HHS T32 HG008962NIH HHS U01 CA206110NINR NIH HHS R01 NR018762NINR NIH HHS R01NR018762Stiftung LebensBlickeTissue Core, Participant Research, Interventions, & MeasurementsUniversity of Utah
6 · The paper itself
Abstract
backgroundCancer-related fatigue (fatigue) is a common and persistent symptom after cancer treatment, yet the role of genetic susceptibility remains unclear.
methodsWe used data from a prospective cohort study called the ColoCare Study, conducted over 5 US sites and Germany. Fatigue was assessed at 5 time points using the European Organisation for the Research and Treatment of Cancer Core Quality of Life Questionnaire fatigue subscale and analyzed as (1) a binary summary measure of the trajectory from diagnosis into survivorship (defined as severe: yes/no), (2) a mean score across all time points, and (3) the highest (ie, worst) score across all time points. We genotyped samples using the Illumina Infinium Global Diversity Array kit with imputation using the National Institutes of Health TOPMed reference panel to conduct a genome-wide association study. The Sum of Single Effects was used to identify independent secondary signals. Transcriptome-wide association studies using the S-PrediXcan and MultiXcan methods were conducted to examine genetic regulation of gene expression. The COLOC package assessed whether variants identified in the genome-wide association study influence gene expression through colocalization analysis.
resultsAmong 1219 participants, 31.0% experienced severe fatigue over the course of their disease. A locus near LINC02505 on chromosome 4 was associated with severe fatigue (rs6531463; odds ratio = 3.25, P = 3.88 × 10-8). When modeling mean fatigue levels, strongly associated variants were identified in or near NEK10 and SLC4A7. Integrative analyses linked the predicted expression of NEK10 in liver tissue to risk of fatigue (P < 4.36 × 10-6). Colocalization analysis identified genetic loci and gene expression near NEK10 (posterior probabilities >0.9).
conclusionsThis study identified novel genetic loci associated with fatigue in patients with colorectal cancer and may be useful for identifying high-risk individuals for preventative strategies.
Indexed as
Colorectal NeoplasmsFatigueGenetic Predisposition to DiseaseAdultAgedFemaleGenome-Wide Association StudyHumansMaleMiddle AgedPolymorphism, Single NucleotideProspective StudiesQuality of Life
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Genetic predisposition to persistent fatigue after a diagnosis of colorectal cancer. · full record | Socratic